Abstract
ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183 .
Keywords: COVID-19; SARS-CoV-2; molnupiravir; nonplasma; pharmacokinetics.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, molnupiravir, nonplasma, pharmacokinetics., 【초록키워드】 Saliva, Antiviral, molnupiravir, pharmacokinetics, nasal, NHC, Registration, SARS-CoV-2 transmission, clinical, Patient, plasma, Concentration, nucleoside, parent nucleoside, enrolled, significantly, correlated, quantified, 【제목키워드】 coronavirus 2, respiratory, prodrug, parent, compartment,
【저자키워드】 COVID-19, SARS-CoV-2, molnupiravir, nonplasma, pharmacokinetics., 【초록키워드】 Saliva, Antiviral, molnupiravir, pharmacokinetics, nasal, NHC, Registration, SARS-CoV-2 transmission, clinical, Patient, plasma, Concentration, nucleoside, parent nucleoside, enrolled, significantly, correlated, quantified, 【제목키워드】 coronavirus 2, respiratory, prodrug, parent, compartment,
{{{ 추상적인 }}}
AGILE Candidate-Specific Trial-2에 등록된 12명의 환자를 대상으로 코로나19 항바이러스제인 molnupiravir의 모체 뉴클레오사이드인 ß-d-N4-hydroxycytidine(NHC)이 SARS-CoV-2 전염 부위에서 정량화되었습니다. 타액, 비강 및 눈물 NHC 농도는 혈장 농도의 3%, 21% 및 22%였습니다. 타액과 비강 NHC는 혈장과 유의한 상관관계가 있었습니다(P < .0001). 임상 시험 등록. NCT04746183 .
{{ 키워드: }} 코로나19; 사스 코로나바이러스 2; 몰누피라비르; 비플라즈마; 약동학.